Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

Cancer

Volumn 123, Issue 3, 2017, Pages 476-484

  de Souza, Jonas A ^a   Yap, Bonnie J ^a   Wroblewski, Kristen ^a   Blinder, Victoria ^b   Araújo, Fabiana S ^c   Hlubocky, Fay J ^a   Nicholas, Lauren H ^d   O'Connor, Jeremy M ^a   Brockstein, Bruce ^e   Ratain, Mark J ^a   Daugherty, Christopher K ^a   Cella, David ^f  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cost of cancer; financial burden; financial toxicity; patient reported outcome (PRO)

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER CHEMOTHERAPY; CANCER PATIENT; COMPREHENSIVE SCORE FOR FINANCIAL TOXICITY; CONTROLLED STUDY; DISTRESS SYNDROME; EMPLOYMENT STATUS; FEMALE; FINANCE; FINANCIAL TOXICITY; HOSPITAL ADMISSION; HUMAN; INCOME; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; PATIENT-REPORTED OUTCOME; QUALITY OF LIFE; QUESTIONNAIRE; RACE; SOLID TUMOR; TEST RETEST RELIABILITY; VALIDITY; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; MIDDLE AGED; NEOPLASMS;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84991107165     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30369     Document Type: Article

References (27)

1. Bestvina CM, Zulling LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10:162–167.
2. Northouse L, Williams Al, Given B, McCorkle R. Psychosocial care for family caregivers of patients with cancer. J Clin Oncol. 2012;30:1227–1234.
3. Pollack, A. For profit, industry seeks cancer drugs. The New York Times. September 1st, 2009. http://www.nytimes.com/2009/09/02/health/research/02cancerdrug.html. Accessed September 20, 2016.
4. de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120:3245–3253.
5. Zafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D. Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015;11:145–150.
6. Lathan CS, Cronin A, Tucker-Seeley R, Zafar SY, Ayanian JZ, Schrag D. Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol. 2016;34:1732–1740.
7. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29:2534–2542.
8. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980–986.
9. The Henry J. Kaiser Family Foundation. What the actuarial values in the Affordable Care Act mean. http://www.kff.org/healthreform/upload/8177.pdf. Accessed September 20, 2016.
10. Ungar L, O'Donnel J. Dilemma over deductibles: costs crippling middle class. http://www.usatoday.com/story/news/nation/2015/01/01/middle-class-workers-struggle-to-pay-for-care-despite-insurance/19841235/. Accessed September 20, 2016.
11. High-deductible health plans, gamble for some, on the rise [transcript]. All Things Considered. National Public Radio. July 28, 2013. http://www.npr.org/2013/07/28/206370593/high-deductible-health-plans-gamble-for-some-on-the-rise. Accessed September 20, 2016.
12. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381–390.
13. Huntington SF, Weiss BM, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2:e408–e416.
14. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
15. Cella DF, Jacobsen PB, Orav EJ, Holland JC, Silberfarb PM, Rafla S. A brief POMS measure of distress for cancer patients. J Chronic Dis. 1987;40:939–942.
16. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA. 2003;290:953–958.
17. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579.
18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
19. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14:967–977.
20. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2-assessing respondent understanding. Value Health. 2011;14:978–988.
21. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19:539–549.
22. Crowne DP, Marlowe D. A new scale of social desirability independent of psychopathology. J Consult Psychol. 1960;24:349–354.
23. Park BW, Lee S, Lee AR, Lee KH, Hwang SY. Quality of life differences between younger and older breast cancer patients. J Breast Cancer. 2011;14:112–118.
24. Faller H, Brahler E, Harter M, et al. Performance status and depressive symptoms as predictors of quality of life in cancer patients. A structural equation modeling analysis. Psychooncology. 2015;24:1456–1462.
25. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. 2nd ed. New York: Oxford University Press; 1995.
26. StataCorp LP. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013.
27. Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8:75s–80s.